Get started
DEXCOM INC COM USD0.001DEXCOM INC COM USD0.001DEXCOM INC COM USD0.001

DEXCOM INC COM USD0.001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0A4M trade ideas

Trade Journal: Long DXCM - 1/29/2020Markets were showing indecision in direction and my bias for the overall market is still bullish. I wanted to add another long today encase this recent market weakness is just a fake out bounce. I do have one short position as a hedge. I decided to go long this DXCM pennant pattern in the daily. DXCM is at all time highs and recently gapped up and ran due to earnings. The pennant pattern also rest right at a level of support and there are strong candlestick patterns (Hammers) rejecting this support. Furthermore, DXCM is resting at the 20MA which is typically where strong stocks like to bounce. Entry - 237.76 Stop loss - 321.90 Target 1 - 250 Target 2 - 268 I plan to use the 20MA has my all-out level.
NASDAQ:DXCMLong
by Trader_Kaji
DexCom Inc - Short OpportunityAs a beginner, I'm trying to learn everything I can about investing for the long term, but also trading in the intermediate and short term. With some successes and failures now under the belt I figure I would share my next opportunity. DexCom's recent earnings release surprised the hell out of analysts, rocketing up 27% on that day and still rising now. Hence, my next short opportunity. A stock continually pushing a 52 week high has no reference point for resistance, therefore it's best to rely on indicators and the trusty candlestick patterns. The volume has been dropping steadily since the earnings, pushing into overbought territory it's never seen before. At the sight of a bearish shooting star, with no increase in volume, go short! Set yourself some reasonable profit margins and stops. Chances are it will test the $185.20 it opened at after earnings, but if you want to be more cautious utilize Fib Retracements (38.2% to 61.8%) from it's peak. Remember, don't be greedy and lock in profits when you reach your goals.
NASDAQ:DXCMShort
by TrendsAreSexy
Dexcom (DXCM) Nears Major Range Breakout LevelDexcom rallied off the lows of the range and is now consolidating near the top of a year-long range. Watching this one closely. About a 3:1 reward to risk with a stop loss below the consolidation and a target between 196 and 200. Want to see high volume on the consolidation breakout to show there is likely enough conviction to break above the range high as well. Can use ATR Stps as a trailing stop as well; adjust inputs to suit your preferences. Disclosure: no trade yet, but may initiate within the next few days if the conditions stay favorable.
NASDAQ:DXCMLong
by CoryMitchell-CMT
DXCM flagSymbol DXCM setup flag Upcoming Earnings Jan 29, 2019 (EST) Feb 21, 2019 (EST) Horizontal S&R: yes 138 Channel S&R: no MA S&R: yes bounced off of 20ma >200ma: yes Volume confirmation: ok Candle Confirmation: yes morning star Stoch Divergence: no Reg Trendline >85: no Short Float: 7% Entry 152 Stop 137 Price Target 182 Risk / Reward: 1:2 Zacks Rank: 2-Buy 2 Style Scores: D Value | A Growth | F Momentum | C VGM Industry Rank: Top 27%(67 out of 255) Industry: Medical - Instruments Any feedback is welcomed.
NASDAQ:DXCMLong
by SR618
DexCom's CGM is the FUTURE.Clearly, that Dec 24 route was the clear buying opportunity, You would've been +40% by now. Is it too late? I'd say NO. If you have the ability to invest on this, and of course, have an awareness on all the geopolitical factors. I think this is a win. If you want to swing, it's also up to you. Here's the thing 1) Let's be clear, DexCom is the leader on CGM (continuous glucose monitoring). BTW, best presentation on JPM Conference. 2) G6 is being sold to partners like tandem, lily, insulet, and novo, basically eating on their lunch. FY18 revenue estimate is from $830m to $850m. ($715m the year before). CEO Kevin Sayer expects revenue to exceed $331m 3) Regarding their collaboration with Verily(GOOG), they expect a product with a lower cost; smaller, longer life, &disposable which benefits those who aren't using CGM yet. 3) The future - There are a lot of people that need to be (and will be) screened, not to mention pre-diabetics. My take: There's so much room to improve the G6 tech. I'm thinking, insulin delivery system kind of like tandem's t:slim. That way, they can serve type 2 diabetics. I like Tandem and I think the collaboration is perfect and I think the Verily product will take the stock higher. Also, a sensor that goes straight to the Apple Watch $AAPL so the patient doesn't have to carry a phone. Strategy: Obtain approval to launch G6 globally; Focus on the rollout to Medicare population. Price Target: Call me crazy but I think DXCM can trade up to Abiomed's level. $320-400. Why? I think this is a monopoly in CGM, and they can execute globally.
NASDAQ:DXCMLong
by UnknownUnicorn2993086